Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05977023). This is a study registration, not published results. Lead sponsor: China Medical University Hospital. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 90 participants (ESTIMATED). Conditions: Bipolar I Disorder. Interventions: DRUG: NMDAE; DRUG: Placebo Cap. Primary outcome measures: Change in Visual Continuous Performance Test , week 0, 8; Change in Wisconsin Card Sorting Test , week 0, 8; Change in Logical Memory Test of the Wechsler Memory Scale , week 0, 8; Digit Span , week 0, 8; Spatial Span , week 0, 8; Category Fluency , week 0, 8; Trail Marking A , week 0, 8; WAIS-III Digit Symbol-Coding , week 0, 8; Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) V2.0 , week 0, 8; Change in Perceived Stress Scale in Perceived Stress Scale , week 0, 2, 4, 6, 8. Brief summary: At present, the treatment of Bipolar I disorder (BD-I), especially its depressive episode (bipolar depression), is still limited, because there is no effective treatment for the associated cognitive impairment and perceived stress. NMDA receptor (NMDAR) dysfunction is associated with BD-I, particularly its cognitive impairment and perceived stress. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of cognitive impairment and perceived stress in the patients with bipolar depression.